targeted immune system activation

introduction to ISA

ISA Pharmaceuticals develops targeted, rationally designed immunotherapeutics for the treatment of cancer and persistent virus infections.


ISA104 for chronic Hepatitis B is in a phase 1 clinical testing. This HEB-PEP trial, run by the Erasmus MC, is currently recruiting patients. Read more.